Oramed Pharmaceuticals (ORMP) FCF Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly FCF Margin came in at 176.1% in Q1 2025, up 55.28% on a QoQ basis from 393.77% in Q2 2023.

Oramed Pharmaceuticals (ORMP) FCF Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 8 years of FCF Margin data on file, last reported at 176.1% in Q1 2025.

Quarterly FCF Margin changed N/A year-over-year to 176.1% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 457.7% (changed N/A YoY) and the FY2025 annual result came in at 457.7%, changed N/A from the prior year.
FCF Margin rose to 176.1% in Q1 2025, from 393.77% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 176.1% in Q1 2025 to a low of 1377.18% in Q1 2022.
A 4-year average of 721.63% and a median of 645.57% in 2023 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 86884 bps in 2023, down 51411 bps in 2023.
Tracing ORMP's FCF Margin over 4 years: stood at 428.08% in 2021, then slumped by 116 bps to 925.88% in 2022, then soared by 57 bps to 393.77% in 2023, then surged by 55 bps to 176.1% in 2025.
The last three FCF Margin figures came in at 176.1% (Q1 2025), 393.77% (Q2 2023), and 863.06% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	Oramed Pharmaceuticals	196.17 Mn	196.17 Mn	-	-

Download Data